80 results about "Mantle lymphoma" patented technology

Differential Methylation Hybridization (DMH) was used to identify novel methylation markers and methylation profiles for hematopoieetic malignancies, leukemia, lymphomas, etc. (e.g., non-Hodgkin's lymphomas (NHL), small B-cell lymphomas (SBCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma (B-CLL / SLL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), etc.). Particular aspects provide novel biomarkers for NHL and subtypes thereof (e.g., MCL, B-CLL / SLL, FL, DLBCL, etc.), AML, ALL and MM, and further provide non-invasive tests (e.g. blood tests) for lymphomas and leukemias. Additional aspects provide markers for diagnosis, prognosis, monitoring responses to therapies, relapse, etc., and further provide targets and methods for therapeutic demethylating treatments. Further aspects provide cancer staging markers, and expression assays and approaches comprising idealized methylation and / or patterns” (IMP and / or IEP) and fusion of gene rankings.

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

The invention relates to a tumour necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) which is capable of selectively signalling through death receptor 4 (DR4), comprising Y at position 189. Preferably the TRAIL further comprises 19 IL and / or 199V; preferably also 201R, 213W and 215D, and / or preferably further comprises 193S. The invention also relates to uses of such TRAIL mutants which are capable of selectively signalling through DR4 in the treatment of cancer, and in the manufacture of medicaments for use in treatment of cancer. Preferably the cancer is chronic lymphocytic leukaemia, mantle cell lymphoma or non-Hodgkin's lymphoma. The invention also relates to kits comprising same.

The present invention features an isolated, intact virus associated with human lymphoma, and originally isolated from a mantle cell lymphoma, referred to herein as a mantle histiocyte retrovirus (MHRV). The invention also features compositions and methods for detecting MHRV, as well as methods and compositions for propagating MHRV in vitro, screening for anti-MHRV agents, and generation of attenuated MHRV strains.

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic Lymphoma (SLL) and multiple myeloma.

The present invention relates to methods of inducing and maintaining an immune response against a B-cell idiotype in a subject using an autologous anti-idiotypic vaccine. In one embodiment, the immune response is induced and maintained for treatment of a B-cell derived malignancy selected from among non-Hodgkin's lymphoma. Hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma, and mantle cell lymphoma.

Methods of detecting, diagnosing, monitoring or managing an XMRV-related disease such as an XMRV-related neuroimmune disease such as chronic fatigue syndrome or an XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity of antibodies against XMRV in a sample from a subject.

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing a SYK inhibitor, or a pharmaceutically acceptable salt thereof, and a antineoplastic or antiinflammatory agent for the treatment of inflammatory, autoimmune and cell proliferative diseases, such as allergic reaction, transplant rejection, rheumatoid arthritis (RA), lupus, multiple sclerosis (MS) or psoriasis undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) (including diffuse large B cell lymphoma (DLBCL)), mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic (SLL), Lymphoma, multiple myeloma, asthma, vasculitis, Idiopathic thrombocytopenic purpura (ITP), Heparin Induced Thrombocytopenia (HIT) and hemolytic anemia.

The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

The invention relates to a novel heterocyclic derivative having a formula (I) and salt. The novel heterocyclic derivative comprises pharmaceutical salt, wherein R1, R2, R3, R4, X, Z and L are defined in the text. Compounds of the novel heterocyclic derivative are a CDK (cyclin-dependent kinase) 4 / 6 inhibitor and an HDAC (histone deacetylase) inhibitor and can be used for treating diseases mediated by CDK4 / 6 and HDAC and disturbances, such as cancer including mantle cell lymphoma, liposarcomata, non-small cell lung cancer, melanomas, squamous cell esophagus cancer and breast cancer. The invention also relates to a pharmaceutical composition containing the compounds provided by the invention, and also relates to application of the compounds or pharmaceutical composition containing the compounds provided by the invention to treatment of related disturbances. <FORMULA I>.

The invention discloses a novel benzo-heterocyclic bipyrimidine inhibitor having CDK or HDAC inhibitory activity. The inhibitor relates to a novel heterocyclic derivative shown in a formula (I) and asalt thereof, including a medicinal salt, wherein R<1>, R<2>, R<3>, R<4> and R<5> and X, Z and L are defined in the description. The compound is a CDK or HDAC inhibitor, and can be used for treating diseases and disorders mediated by CDK or HDAC, such as cancer, including mantle cell lymphoma, liposarcoma, non-small cell lung cancer, melanoma, squamous cell esophageal cancer, breast cancer, etc. Apharmaceutical composition containing the compound is also related. To treat related disorders by using the compound or the pharmaceutical composition containing the compound is also related. The structure of the novel heterocyclic derivative is shown in the formula (I).

The method and the kit are useful as tools for classifying a patient diagnosed with mantle cell lymphoma into the category of: indolent or conventional. The method comprises: a) providing a sample from a patient suffering from mantle cell lymphoma; b) determining the level of expression of at least one gene selected from the group consisting of: RNGTT, HDGFRP3, FARP1, HMGB3, LGALS3BP, PON2, CDK2AP1, DBN1, CNR1, CNN3, SOX11, SETMAR and CSNK1E in said sample; and c) comparing the level of expression of each of the measured genes with respect to the level of expression of the same genes in a control sample; wherein the absence of expression or the underexpression of said genes with respect to the same genes in said control sample is indicative of the indolent clinical course of the MCL.

The present disclosure relates to a method of treatment of a human patient suffering from a B-cell lymphoproliferative disorders such as B-cell chronic lymphocytic leukemia (B-CLL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), and Waldenström syndrome (WS), by the administration of a therapeutically effective amount of 5-aminoimidazole-4-carboxamide riboside (acadesine) or its precursors (eg. its mono-, di- and tri-5′-phosphates). This makes acadesine and its bioprecursors (eg. its mono-, di- and tri-5′-phosphates) useful as therapeutic agents for B-cell lymphoproliferative disorders in humans. The surprising feature that T cells are virtually not affected means that the side effect (immunosuppression) is minor, what represents a therapeutical advantage of acadesine over cladribine, fludarabine and other nucleosides known in the art.

The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (A), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula I:or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

A method for determining presence of lymphoma in a patient is disclosed. A sample of bone marrow, thymus, spleen, lymph nodes, lymph and / or lymphocytes taken from the patient t is assayed to determine expression of CDK9 and CYCLIN T1. The presence of CDK9 and / or CYCLIN T1 is indicative of a lymphoma other than a mantle cell lymphoma or marginal zone lymphoma in the patient.

The invention generally relates to substituted benzofuranyl compounds and, more particularly, to a compound represented by Structural Formula 1a: (I) or a pharmaceutically acceptable salt thereof. The invention also includes the synthesis and use of the compound of Structural Formula 1a, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of diseases or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

The invention generally relates to substituted benzothiophenyl, substituted benzothiazolyl, substituted indolyl and substituted benzoimidazolyl compounds and, more particularly, to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, inflammatory diseases or an autoimmune system disease (e.g., a T-Cell mediated autoimmune disesase).

The invention generally relates to cyclic compounds and, more particularly, to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

The invention provides a preparation method and applications of a 4-phenoxy phenyl pyrazolo pyrimidine amide derivative. The compound has a structure represented by a formula (I), wherein X and Y aretwo linking groups, X is selected from benzyl, substituted benzyl, piperidyl and C1-6 straight-chain or branched-chain alkyl, Y is -(CH2)n-, n is any integer selected from 0-4, R is selected from hydroxyl, hydroxyamino and o-phenylenediamine, and the structure of the formula (I) comprises a racemate and a stereoisomer. The compound has a BTK / HDAC double-target inhibition effect and growth inhibition activity on T cell leukemia cells and mantle cell lymphoma cells, and is used for preparing antitumor drugs.

The invention generally relates to substituted benzofuranyl compounds and, more particularly, to a compound represented by Structural Formula 1a: (I) or a pharmaceutically acceptable salt thereof. The invention also includes the synthesis and use of the compound of Structural Formula 1a, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of diseases or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

The invention provides a benzyloxy aromatic ring structure compound represented by a general formula (I), a stereoisomer, an enantiomer or a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the same, and uses thereof. The compound shown in the general formula (I) can be used for preparing a small-molecule inhibitor of PD1 / PDL1 interaction, and can be used for preventing and / or treating diseases related to PD1 / PDL1 interaction, especially cancers, such as non-small cell lung cancer, small cell lung cancer, melanoma, head and neck cancer, kidney cancer, bladder cancer, local advanced or metastatic urothelial cancer, breast cancer, cervical cancer, metastatic Merkel cell cancer, prostate cancer, liver cancer, intestinal cancer, stomach cancer, multiple myeloma, mantle cell lymphoma, diffuse large B cell lymphoma, liver cancer, hodgkin lymphoma, chronic lymphocytic leukemia, squamous cell carcinoma and the like.

The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (I) or (II), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

The invention discloses preparation and applications for a novel 1,1-cyclopropyl diamide derivative, and relates to a novel 1,1-cyclopropyl diamide derivative having a formula (I) and a salt thereof,including a medicinal salt, wherein R1, R2, R3, R4 and R5 and X, Z and L are defined as the description. The compound can be used for treating HIV and cancer diseases including lung cancer, liver cancer, breast cancer, lymphoma, mantle cell lymphoma, liposarcoma, melanoma, squamous cell esophageal cancer, etc. The pharmaceutical composition can be prepared to dosage forms suitable for absorption and utilization of mammal tissues and organs, and has good application prospects on treating cancers and HIV diseases. The pharmaceutical composition containing the compound is also related. The structural formula of the 1,1-cyclopropyl diamide derivative is shown as the formula (I).

—use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), transformed lymphoma (TL), or peripheral T-cell lymphoma (PTCL); —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), transformed lymphoma (TL), or peripheral T-cell lymphoma (PTCL); —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of the expression of PI3K isoforms, BTK and IKK, BCR activation, BCR downstream activation of NFKB pathway, c-Myc, EZH2, for predicting the sensitivity and / or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and / or to overcome resistance; and —a method of determining the level of a component of one or more of the expression of PI3K isoforms, BTK and IKK, BCR activation, BCR downstream activation of NFKB pathway, c-Myc, EZH2.

The invention relates to the field of medicaments, and in particular relates to polypeptide with functions of inhibiting Cyclin D protein expression and treating mantle cell lymphoma, the sequence is ETIRRAYPDAANLLNDRVL which is a brand-new sequence, the polypeptide is capable of in vitro inhibiting Mino cell proliferation and migration of the mantle cell lymphoma cell and treating the mantle cell lymphoma; the survival rate of mice is successfully increased in a body bearing cancer model experiment, and the potential new medicine development value is provided.

The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being venetoclax or palbociclib. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment or prophylaxis of non-Hodgkin's lymphoma (hereinafter abbreviated to “NHL”), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (hereinafter abbreviated to “FL”), chronic lymphocytic leukaemia (hereinafter abbreviated to “CLL”), marginal zone lymphoma (hereinafter abbreviated to “MZL”), splenic marginal zone lymphoma (hereinafter abbreviated to “SMZL”), diffuse large B-cell lymphoma (hereinafter abbreviated to “DLBCL”), mantle cell lymphoma (MCL), transformed lymphoma (hereinafter abbreviated to “TL”), or peripheral T-cell lymphoma (hereinafter abbreviated to “PTCL”).

The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of FasL to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (ASCT) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory / recidivating Hodgkin's disease. Such therapy is nowadays also contemplated for selected patients with low-grade lymphomas (chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma) and for patients with acute myeloid leukemia (AML). Current treatments for cell purging include chemotherapy and antibody cocktails. These treatments are often toxic on stem cells and not efficient in eliminating cancer cells. Thus, there is an unmet medical need for cell purging in ASCT which this project will address.